ArticleTherapeutic advances in medical oncology2025

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.

Peter Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.